- Abstract viewed - 0 times
- PDF downloaded - 0 times
- Supplementary File 1 downloaded - 0 times
- Supplementary File 2 downloaded - 0 times
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Affiliations
Karn Wijarnpreecha
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
Elizabeth S Aby
Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota, United States
Hassan Ghoz
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
Wisit Cheungpasitporn
Department of Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, United States
Frank J Lukens
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
Denise M Harnois
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
Patompong Ungprasert
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, United States
How to Cite
Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis
- Karn Wijarnpreecha ,
- Elizabeth S Aby ,
- Hassan Ghoz ,
- Wisit Cheungpasitporn ,
- Frank J Lukens ,
- Denise M Harnois ,
- Patompong Ungprasert
Vol 29 No 4: December 2020
Section: Systematic Review and Meta-Analysis
Pages: 629-635
Abstract
Background and Aims: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.
Methods: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.
Results: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).
Conclusions: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.